Table 1. Patient’s baseline... | American Society of Hematology

Table 1.

Patient’s baseline characteristics and CD56 expression on BM-MM cells

Patient no.	Age, y/sex	Clinical stage (ISS)	Monoclonal Ig	% PCs in BM	CD56 expression on MM cells
1	60/M	III	IgG κ	50	++
2	65/M	I	IgG κ	28	++
3	59/M	III	IgG κ	60	++
4	60/F	I	IgG κ	60	+
5	65/F	III	IgA κ	50	+
6	67/F	III	IgG κ	40	++
7	62/F	II	IgG κ	70	+
8	60/M	III	IgG κ	70	++
9	54/F	I	IgG κ	35	++
10	65/M	I	IgG κ	50	++
11	60/F	II	IgG κ	30	++
12	62/M	II	IgA κ	35	++
13	58/F	I	IgG λ	60	+
14	65/M	II	IgG κ	50	++
15	70/M	I	IgG κ	40	++
16	62/F	III	IgA κ	50	++
17	65/F	III	IgG λ	40	++
18	63/F	II	IgA κ	45	++
19	64/M	III	IgG λ	38	++
20	60/F	III	IgG λ	80	+
21	61/F	III	IgG λ	38	++
22	65/M	III	IgG κ	30	+
23	63/F	II	IgG λ	35	+

Patient no.	Age, y/sex	Clinical stage (ISS)	Monoclonal Ig	% PCs in BM	CD56 expression on MM cells
1	60/M	III	IgG κ	50	++
2	65/M	I	IgG κ	28	++
3	59/M	III	IgG κ	60	++
4	60/F	I	IgG κ	60	+
5	65/F	III	IgA κ	50	+
6	67/F	III	IgG κ	40	++
7	62/F	II	IgG κ	70	+
8	60/M	III	IgG κ	70	++
9	54/F	I	IgG κ	35	++
10	65/M	I	IgG κ	50	++
11	60/F	II	IgG κ	30	++
12	62/M	II	IgA κ	35	++
13	58/F	I	IgG λ	60	+
14	65/M	II	IgG κ	50	++
15	70/M	I	IgG κ	40	++
16	62/F	III	IgA κ	50	++
17	65/F	III	IgG λ	40	++
18	63/F	II	IgA κ	45	++
19	64/M	III	IgG λ	38	++
20	60/F	III	IgG λ	80	+
21	61/F	III	IgG λ	38	++
22	65/M	III	IgG κ	30	+
23	63/F	II	IgG λ	35	+

, CD56+ MM cells (30%-69%); ++, CD56+ MM cells (70%-100%); F, female; ISS, International Staging System; M, male.